Theriva Biologics, Inc. (TOVX)
USD 1.17
(-0.29%)
USD 1.17
(-0.29%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 21.43 Million USD | -0.7% |
| 2022 | 21.58 Million USD | 51.19% |
| 2021 | 14.27 Million USD | 40.49% |
| 2020 | 10.16 Million USD | -35.13% |
| 2019 | 15.66 Million USD | -10.86% |
| 2018 | 17.57 Million USD | -33.07% |
| 2017 | 26.25 Million USD | -33.12% |
| 2016 | 39.25 Million USD | -4.22% |
| 2015 | 40.98 Million USD | 99.88% |
| 2014 | 20.5 Million USD | 66.16% |
| 2013 | 12.33 Million USD | -28.67% |
| 2012 | 17.29 Million USD | 191.82% |
| 2011 | 5.92 Million USD | 38.48% |
| 2010 | 4.28 Million USD | 13.11% |
| 2009 | 3.78 Million USD | -48.29% |
| 2008 | 7.31 Million USD | -27.81% |
| 2007 | 10.13 Million USD | 147.0% |
| 2006 | 4.1 Million USD | 211.14% |
| 2005 | 1.31 Million USD | 0.0% |
| 2002 | 8.25 Million USD | -22.68% |
| 2001 | 10.68 Million USD | 59.82% |
| 2000 | 6.68 Million USD | 15.53% |
| 1999 | 5.78 Million USD | 5.19% |
| 1998 | 5.5 Million USD | -45.54% |
| 1997 | 10.1 Million USD | 29.49% |
| 1996 | 7.8 Million USD | 5.41% |
| 1995 | 7.4 Million USD | 15.63% |
| 1994 | 6.4 Million USD | 72.97% |
| 1993 | 3.7 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.38 Million USD | -18.14% |
| 2024 Q1 | 5.35 Million USD | -8.32% |
| 2023 Q4 | 5.83 Million USD | 38.43% |
| 2023 Q3 | 4.21 Million USD | -27.53% |
| 2023 Q1 | 5.17 Million USD | -29.36% |
| 2023 Q2 | 5.82 Million USD | 12.4% |
| 2023 FY | 21.95 Million USD | 1.74% |
| 2022 Q4 | 7.33 Million USD | 46.19% |
| 2022 Q3 | 5.01 Million USD | 0.58% |
| 2022 Q2 | 4.98 Million USD | 17.24% |
| 2022 Q1 | 4.25 Million USD | -19.24% |
| 2022 FY | 21.58 Million USD | 51.19% |
| 2021 Q4 | 5.26 Million USD | 60.76% |
| 2021 FY | 14.27 Million USD | 40.49% |
| 2021 Q1 | 2.53 Million USD | 19.0% |
| 2021 Q2 | 3.19 Million USD | 26.01% |
| 2021 Q3 | 3.27 Million USD | 2.44% |
| 2020 FY | 10.16 Million USD | -35.13% |
| 2020 Q1 | 3.02 Million USD | -5.67% |
| 2020 Q2 | 2.88 Million USD | -4.59% |
| 2020 Q3 | 2.11 Million USD | -26.93% |
| 2020 Q4 | 2.13 Million USD | 0.99% |
| 2019 Q2 | 3.63 Million USD | 1.85% |
| 2019 Q4 | 3.21 Million USD | -38.76% |
| 2019 Q3 | 5.24 Million USD | 44.09% |
| 2019 FY | 15.66 Million USD | -10.86% |
| 2019 Q1 | 3.57 Million USD | 9.64% |
| 2018 Q2 | 5 Million USD | 0.26% |
| 2018 Q1 | 4.99 Million USD | -13.71% |
| 2018 Q3 | 4.32 Million USD | -13.65% |
| 2018 FY | 17.57 Million USD | -33.07% |
| 2018 Q4 | 3.25 Million USD | -24.58% |
| 2017 Q3 | 5.84 Million USD | -9.78% |
| 2017 Q1 | 8.14 Million USD | -20.14% |
| 2017 Q4 | 5.78 Million USD | -1.01% |
| 2017 FY | 26.25 Million USD | -33.12% |
| 2017 Q2 | 6.47 Million USD | -20.54% |
| 2016 Q4 | 10.2 Million USD | 11.45% |
| 2016 Q1 | 10.58 Million USD | -7.13% |
| 2016 Q2 | 9.31 Million USD | -12.0% |
| 2016 Q3 | 9.15 Million USD | -1.66% |
| 2016 FY | 39.25 Million USD | -4.22% |
| 2015 Q3 | 11.65 Million USD | 19.73% |
| 2015 Q2 | 9.73 Million USD | 18.56% |
| 2015 Q1 | 8.2 Million USD | 15.58% |
| 2015 FY | 40.98 Million USD | 99.88% |
| 2015 Q4 | 11.39 Million USD | -2.21% |
| 2014 Q2 | 4.65 Million USD | 21.15% |
| 2014 Q1 | 3.83 Million USD | -10.16% |
| 2014 Q4 | 7.1 Million USD | 44.59% |
| 2014 FY | 20.5 Million USD | 66.16% |
| 2014 Q3 | 4.91 Million USD | 5.59% |
| 2013 FY | 12.33 Million USD | -28.67% |
| 2013 Q3 | 3.36 Million USD | 36.73% |
| 2013 Q4 | 4.27 Million USD | 26.98% |
| 2013 Q1 | 2.24 Million USD | -81.15% |
| 2013 Q2 | 2.46 Million USD | 9.87% |
| 2012 Q3 | 1.83 Million USD | 6.56% |
| 2012 Q4 | 11.88 Million USD | 547.39% |
| 2012 FY | 17.29 Million USD | 191.82% |
| 2012 Q2 | 1.72 Million USD | -7.07% |
| 2012 Q1 | 1.85 Million USD | -25.17% |
| 2011 Q1 | 1.5 Million USD | 69.61% |
| 2011 Q2 | 973.92 Thousand USD | -35.32% |
| 2011 Q3 | 970.76 Thousand USD | -0.32% |
| 2011 Q4 | 2.47 Million USD | 155.21% |
| 2011 FY | 5.92 Million USD | 38.48% |
| 2010 Q1 | 1.15 Million USD | -0.05% |
| 2010 FY | 4.28 Million USD | 13.11% |
| 2010 Q2 | 1.22 Million USD | 5.8% |
| 2010 Q4 | 887.81 Thousand USD | -13.22% |
| 2010 Q3 | 1.02 Million USD | -16.26% |
| 2009 Q3 | 677.3 Thousand USD | -23.0% |
| 2009 FY | 3.78 Million USD | -48.29% |
| 2009 Q2 | 879.6 Thousand USD | -19.26% |
| 2009 Q1 | 1.08 Million USD | 18.4% |
| 2009 Q4 | 1.15 Million USD | 70.56% |
| 2008 FY | 7.31 Million USD | -27.81% |
| 2008 Q2 | 1.8 Million USD | -42.38% |
| 2008 Q4 | 920.09 Thousand USD | -37.41% |
| 2008 Q3 | 1.46 Million USD | -18.42% |
| 2008 Q1 | 3.12 Million USD | -2.77% |
| 2007 Q3 | 2.17 Million USD | 18.88% |
| 2007 Q1 | 2.92 Million USD | -28.71% |
| 2007 Q2 | 1.82 Million USD | -37.42% |
| 2007 FY | 10.13 Million USD | 147.0% |
| 2007 Q4 | 3.21 Million USD | 48.02% |
| 2006 Q1 | 515.53 Thousand USD | 0.0% |
| 2006 Q2 | 4363.00 USD | -99.15% |
| 2006 Q3 | 3017.00 USD | -30.85% |
| 2006 FY | 4.1 Million USD | 211.14% |
| 2006 Q4 | 4.09 Million USD | 135703.68% |
| 2005 FY | 1.31 Million USD | 0.0% |
| 2003 Q1 | 679.39 Thousand USD | -19.62% |
| 2002 Q3 | 1.17 Million USD | -62.06% |
| 2002 FY | 8.25 Million USD | -22.68% |
| 2002 Q1 | 3.13 Million USD | 4.05% |
| 2002 Q2 | 3.1 Million USD | -0.88% |
| 2002 Q4 | 845.23 Thousand USD | -28.23% |
| 2001 Q3 | 2.75 Million USD | -10.88% |
| 2001 Q2 | 3.08 Million USD | 68.46% |
| 2001 Q1 | 1.83 Million USD | -8.48% |
| 2001 FY | 10.68 Million USD | 59.82% |
| 2001 Q4 | 3 Million USD | 9.38% |
| 2000 Q1 | 1.62 Million USD | -3.41% |
| 2000 Q4 | 2 Million USD | 38.44% |
| 2000 Q3 | 1.44 Million USD | -9.95% |
| 2000 Q2 | 1.6 Million USD | -1.3% |
| 2000 FY | 6.68 Million USD | 15.53% |
| 1999 Q2 | 1.4 Million USD | 16.67% |
| 1999 FY | 5.78 Million USD | 5.19% |
| 1999 Q1 | 1.2 Million USD | 20.0% |
| 1999 Q4 | 1.68 Million USD | 12.35% |
| 1999 Q3 | 1.5 Million USD | 7.14% |
| 1998 Q3 | 1.2 Million USD | 9.09% |
| 1998 Q4 | 1 Million USD | -16.67% |
| 1998 FY | 5.5 Million USD | -45.54% |
| 1998 Q2 | 1.1 Million USD | -50.0% |
| 1998 Q1 | 2.2 Million USD | 10.0% |
| 1997 Q4 | 2 Million USD | 5.26% |
| 1997 Q2 | 3.4 Million USD | 25.93% |
| 1997 Q1 | 2.7 Million USD | 22.73% |
| 1997 FY | 10.1 Million USD | 29.49% |
| 1997 Q3 | 1.9 Million USD | -44.12% |
| 1996 Q1 | 1.7 Million USD | -10.53% |
| 1996 Q2 | 1.7 Million USD | 0.0% |
| 1996 Q4 | 2.2 Million USD | 0.0% |
| 1996 Q3 | 2.2 Million USD | 29.41% |
| 1996 FY | 7.8 Million USD | 5.41% |
| 1995 Q4 | 1.9 Million USD | -9.52% |
| 1995 Q1 | - USD | 100.0% |
| 1995 FY | 7.4 Million USD | 15.63% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q3 | 2.1 Million USD | 0.0% |
| 1994 Q2 | - USD | -100.0% |
| 1994 Q1 | 400 Thousand USD | -63.64% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | 6.4 Million USD | 72.97% |
| 1994 Q4 | -6.4 Million USD | 0.0% |
| 1993 Q3 | 1.5 Million USD | 200.0% |
| 1993 FY | 3.7 Million USD | 0.0% |
| 1993 Q1 | 400 Thousand USD | 0.0% |
| 1993 Q4 | 1.1 Million USD | -26.67% |
| 1993 Q2 | 500 Thousand USD | 25.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 33.187% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -131.237% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -83.973% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 58.787% |
| Azitra, Inc. | 8.3 Million USD | -158.13% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -139.774% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -212.301% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 26.08% |
| CEL-SCI Corporation | 31.47 Million USD | 31.913% |
| iBio, Inc. | 16.85 Million USD | -27.119% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 35.071% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | -6.187% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | 13.8% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -53.83% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -66.158% |
| NanoViricides, Inc. | 8.51 Million USD | -151.652% |
| Oragenics, Inc. | 5.45 Million USD | -293.089% |
| BiomX Inc. | 26.81 Million USD | 20.075% |
| BiomX Inc. | 26.81 Million USD | 20.075% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 33.137% |
| Palatin Technologies, Inc. | 34.67 Million USD | 38.186% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 46.175% |